Cordyceps

Metadata

Regulatory Status

Chinese Pharmacopoeia

• Listed: Yes. Dong Chong Xia Cao (Cordyceps) is an official drug in the Chinese Pharmacopoeia (2020 edition).
• Official species: Ophiocordyceps sinensis (the wild caterpillar-fungus complex).
• Traditional indications: Tonifying the kidney and supplementing the lung; used for kidney deficiency with impotence, seminal emission, aching lumbar region and knees, chronic cough with dyspnea from lung deficiency, and hemoptysis due to consumptive disease.
• Official dose: 3—9 g in decoction.

United States

• Dietary supplement: Yes. Widely sold under DSHEA. Cs-4 mycelium and cultivated C. militaris fruiting body products are the predominant commercial forms.
• FDA GRAS status: No specific GRAS determination for cordyceps extracts.

European Union

• Novel food: C. militaris mycelium biomass has received novel food authorization in certain EU member states. Whole fruiting body products and concentrated extracts may require separate authorization depending on the preparation and member state.
• EMA/HMPC: No assessment report or monograph. Cordyceps falls entirely outside the European phytotherapy regulatory framework, originating from TCM and Tibetan traditions.
• Commission E / ESCOP: No monographs exist.

Japan and Korea

• Japan: Not listed in the Japanese Pharmacopoeia. Available as a health food and supplement.
• Korea: Recognized in Korean traditional medicine (Hanbang). C. militaris is cultivated commercially in Korea and widely used in functional food products.

Tibetan and Nepali Traditional Medicine

• Tibetan name: Yartsa gunbu (“summer grass, winter worm”).
• Traditional use: Collected at 3,000—5,000 m altitude on the Tibetan Plateau and Himalayan regions for centuries as a general tonic and aphrodisiac.
• Economic significance: Wild O. sinensis harvesting represents a major income source for Tibetan and Nepali highland communities, sometimes exceeding 50% of household income.

Conditions & Indications

Primary: Energy, Exercise Performance, and Fatigue (Moderate Evidence)

• Physical endurance and VO2 max: Multiple small RCTs demonstrate improvements in maximal oxygen consumption and time-to-exhaustion in elderly and younger adult populations. The proposed mechanism involves enhanced mitochondrial ATP production and improved oxygen utilization via cordycepin and adenosine signaling. Effects appear more pronounced in untrained or elderly individuals than in trained athletes.
• Fatigue reduction: Both traditional use and clinical trials support anti-fatigue effects, particularly in elderly or debilitated individuals. Cs-4 supplementation has shown significant improvements in subjective fatigue scores and exercise tolerance in controlled trials.

Secondary: Respiratory Support (Preliminary Evidence)

• Lung function: Traditional TCM indication for “supplementing the lung.” Limited clinical evidence from Chinese trials suggests improved respiratory function in chronic obstructive pulmonary disease (COPD) and asthma patients when used as adjunctive therapy. The Zhu et al. (1998) systematic review found evidence for improved respiratory symptoms across multiple Chinese clinical trials.
• Oxygen utilization: Adenosine-mediated vasodilation and enhanced mitochondrial efficiency may improve tissue oxygenation, consistent with traditional high-altitude use among Tibetan populations.

Secondary: Kidney and Sexual Health (Preliminary Evidence)

• Renal support: Zhu et al. (1998) meta-analysis of Chinese clinical trials found evidence for improved renal function markers (creatinine clearance, reduced proteinuria) in chronic kidney disease patients receiving cordyceps as adjunctive therapy.
• Sexual function and libido: Traditional aphrodisiac use is supported by small clinical studies showing improved libido and sexual function, particularly in elderly men. Proposed mechanisms include testosterone modulation and nitric oxide-mediated vasodilation.

Emerging: Immune Modulation and Other (Preclinical)

• Immune modulation: Beta-glucan polysaccharides stimulate innate immune function (macrophage activation, NK cell activity); cordycepin simultaneously demonstrates anti-inflammatory properties. The net effect is immunomodulatory rather than purely immunostimulant.
• Anti-tumor activity: Cordycepin demonstrates broad anti-proliferative activity in vitro through inhibition of mRNA polyadenylation, apoptosis induction, and AMPK activation. No clinical trial evidence for anti-cancer efficacy in humans.
• Blood glucose regulation: Animal studies and small pilot trials suggest hypoglycemic activity through enhanced insulin sensitivity and modulation of hepatic glucose metabolism. Insufficient clinical evidence for recommendation.

Mechanism of Action

Cordycepin as Adenosine Analog

Cordycepin (3’-deoxyadenosine) is the signature bioactive of the Cordyceps genus. It is a structural analog of adenosine, differing only by the absence of a hydroxyl group at the 3’ position of the ribose ring. Cordycepin interacts with adenosine receptors (A1, A2A, A2B, A3) and adenosine metabolic pathways. A1 receptor agonism may mediate cardioprotective effects; A2A agonism contributes to vasodilation and anti-inflammatory activity; A3 receptor modulation has been linked to anti-proliferative effects in preclinical cancer models. Cordycepin is also incorporated into RNA, causing premature chain termination and inhibiting mRNA polyadenylation — the mechanism underlying its anti-proliferative activity.

Species difference: Cultivated C. militaris fruiting bodies typically contain 3—8 mg/g cordycepin, significantly higher than wild O. sinensis (which often contains less than 1 mg/g). Cs-4 mycelium products contain variable cordycepin levels depending on fermentation conditions.

Mitochondrial Bioenergetics Enhancement

Cordyceps extracts and cordycepin upregulate mitochondrial biogenesis via AMPK/PGC-1alpha signaling, increase cellular ATP/ADP ratios, and enhance oxidative phosphorylation efficiency. This mechanism is consistent with observed improvements in aerobic exercise performance and resistance to fatigue, and provides the pharmacological basis for the energy-performance category.

Beta-Glucan Immune Stimulation

Cordyceps polysaccharides, primarily beta-(1,3)-D-glucans with (1,6) branching, activate innate immune cells through dectin-1 and toll-like receptor 2 (TLR-2) signaling. This stimulates macrophage phagocytosis, increases NK cell cytotoxicity, and promotes dendritic cell maturation. The polysaccharide profile of cultivated C. militaris is broadly comparable to wild O. sinensis, though quantitative differences in specific polysaccharide fractions exist.

Anti-Inflammatory Activity

Cordycepin inhibits NF-kB nuclear translocation and downstream pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6), partly through adenosine A2A receptor activation and partly through direct inhibition of IKK phosphorylation. This dual anti-inflammatory mechanism complements the immunostimulatory beta-glucan activity, yielding an overall immunomodulatory rather than purely immunostimulant profile.

Adenosine-Mediated Vasodilation

Adenosine and cordycepin promote vasodilation through A2A and A2B receptor-mediated smooth muscle relaxation, improving peripheral blood flow and tissue oxygenation. Combined with mitochondrial enhancement, this provides a coherent pharmacological basis for the exercise performance and respiratory benefits observed in clinical trials.

Pharmacokinetic Note

Cordycepin has a short in vivo half-life due to rapid deamination by adenosine deaminase (ADA). Co-administration with ADA inhibitors (such as pentostatin) dramatically extends cordycepin half-life in preclinical models — relevant primarily to oncology research. The bioavailability of cordycepin from whole extract preparations may differ from isolated compound studies due to the presence of other constituents that may modulate absorption and metabolism.

Clinical Evidence Summary

Clinical evidence for cordyceps draws from trials using Cs-4 mycelium preparations, cultivated C. militaris fruiting body extracts, and traditional O. sinensis. Most RCTs are small, and several influential early studies from China have not been independently replicated.

Exercise Performance and VO2 Max

Fatigue and General Vitality

Renal Function

Important Historical Context

In 1993, the Chinese women’s Olympic distance running team shattered multiple world records. Their coach, Ma Junren, attributed the performances to a regimen that included cordyceps supplementation. These claims generated worldwide commercial interest but were never independently verified in controlled studies. Several athletes from this program later tested positive for banned substances. The episode illustrates the critical importance of distinguishing anecdotal claims from controlled trial evidence.

Evidence Limitations

• Most positive RCTs have small sample sizes (n = 20—28 for exercise performance studies).
• The Zhu et al. (1998) systematic review compiled Chinese-language trials of variable methodological quality that have not been independently replicated in Western research settings.
• Exercise performance results are inconsistent: Parcell et al. (2004) found no benefit in trained cyclists, suggesting effects may be more pronounced in untrained, elderly, or deconditioned populations.
• Heterogeneity of preparations (Cs-4 mycelium, C. militaris fruiting body, various extracts) makes cross-study comparison difficult.
• Publication bias is a concern, particularly for Chinese-language trials.
• No large (n > 100), multi-center, independently funded RCTs have been published as of this writing.

Safety Profile

General Assessment

Cordyceps preparations (Cs-4 mycelium, cultivated C. militaris) appear generally well-tolerated in published clinical trials at standard doses. Traditional use of O. sinensis spans over 1,500 years in TCM and Tibetan medicine. Systematic long-term safety data from large controlled trials is lacking.

Contraindications

• Pregnancy and lactation: Contraindicated due to insufficient safety data. No human studies in pregnant women. Some preclinical evidence suggests potential effects on sex hormones.
• Autoimmune disease: Theoretical concern that immunostimulatory beta-glucans could exacerbate autoimmune conditions (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis). Clinical evidence for this interaction is lacking but the theoretical concern is plausible.
• Pre-surgical: Discontinue at least 2 weeks before surgery due to potential antiplatelet activity and interaction with anesthesia.

Drug Interactions

• Anticoagulants and antiplatelets (warfarin, heparin, aspirin, clopidogrel): Cordycepin has demonstrated antiplatelet and mild anticoagulant activity in vitro and in animal models. Theoretical increased bleeding risk with concurrent anticoagulant therapy. Monitor INR closely if co-administered with warfarin.
• Immunosuppressants (cyclosporine, tacrolimus, cyclophosphamide): Cordyceps beta-glucans may counteract immunosuppressive therapy by stimulating immune function. Avoid concurrent use in transplant patients or those on immunosuppressive regimens without physician supervision.
• Theophylline: Cordycepin, as an adenosine analog, may interact with adenosine receptor signaling pathways also affected by theophylline (an adenosine receptor antagonist). Theoretical antagonistic interaction; clinical significance uncertain but warrants caution.
• Antidiabetic medications: Cordyceps may have additive hypoglycemic effects. Monitor blood glucose if co-administered with insulin or oral hypoglycemics.
• CYP450 substrates: Limited in vitro data suggest potential inhibition of CYP3A4 and CYP2D6. Clinical significance is uncertain.

Side Effects (at Recommended Doses)

• Common: Generally well-tolerated. Mild GI discomfort (nausea, diarrhea, dry mouth) reported infrequently.
• Uncommon: Allergic reactions in individuals with mold or fungal sensitivities.
• Rare: Case reports of lead poisoning from contaminated wild-harvested O. sinensis products.

Contamination and Quality Concerns

• Wild O. sinensis: Due to extreme value (exceeding gold by weight), adulteration and contamination are significant concerns. Heavy metal contamination (lead, arsenic, cadmium) has been documented. Lead-filled specimens to increase sale weight have been reported.
• Cultivated C. militaris: Generally free of heavy metal concerns under GMP conditions, but third-party testing for heavy metals, arsenic, and microbial contamination is advisable.
• Species verification: DNA authentication is recommended, as substitution of cheaper fungal species is widespread in the global market.

Clinical Dosage

Cs-4 Mycelium (Fermented O. sinensis Mycelium)

• Standard dose: 3—4.5 g/day of Cs-4 mycelium powder, divided into 2—3 doses
• This is the most clinically studied preparation (Chen et al. 2010, Yi et al. 2004, Parcell et al. 2004)
• Standardization: Typically standardized to adenosine content (>0.14%) and/or mannitol content (>7%)

Cultivated C. militaris Fruiting Body Extract

• Standard dose: 1—3 g/day of dried fruiting body powder or equivalent extract
• Cordycepin content: Cultivated C. militaris typically contains 3—8 mg/g cordycepin (significantly higher than wild O. sinensis)
• Extraction method: Hot-water extraction captures polysaccharides; dual extraction (hot water + ethanol) captures both polysaccharides and cordycepin

Cordycepin-Standardized Extracts

• Dose varies by product depending on cordycepin concentration
• Typical range: 200—1,000 mg of extract standardized to a specified cordycepin content
• Note: Standardization to cordycepin is relatively new and dosing is largely empirical

Traditional O. sinensis (Decoction)

• Chinese Pharmacopoeia dose: 3—9 g/day in decoction
• Rarely used today due to extreme cost and ecological unsustainability
• Not recommended as a practical clinical option; cultivated C. militaris or Cs-4 are preferred alternatives

Form Selection Guidance

The choice between C. militaris fruiting body and Cs-4 mycelium depends on the clinical goal. For cordycepin-driven effects (anti-inflammatory, exercise performance via adenosine-analog activity), C. militaris fruiting body extracts offer higher cordycepin content. For immune modulation via polysaccharides, both forms are effective. Cs-4 has a longer track record in clinical trials. Dual-extraction products that capture both water-soluble polysaccharides and alcohol-soluble cordycepin provide the broadest bioactive spectrum.

Sources

• Chen S, Li Z, Krochmal R, Abrazado M, Kim W, Cooper CB. Effect of Cs-4 (Cordyceps sinensis) on exercise performance in healthy older subjects: a double-blind, placebo-controlled trial. J Altern Complement Med. 2010;16(5):585-590
• Hirsch KR, Smith-Ryan AE, Roelofs EJ, Trexler ET, Mock MG. Cordyceps militaris improves tolerance to high-intensity exercise after acute and chronic supplementation. J Diet Suppl. 2017;14(1):42-53
• Yi X, Xi-zhen H, Jia-shi Z. Randomized double-blind placebo-controlled clinical trial and assessment of fermentation product of Cordyceps sinensis (Cs-4) in enhancing aerobic capacity and respiratory function of the healthy elderly volunteers. Chin J Integr Med. 2004;10(3):187-192
• Parcell AC, Smith JM, Schulthies SS, Myrer JW, Fellingham G. Cordyceps sinensis (CordyMax Cs-4) supplementation does not improve endurance exercise performance. Int J Sport Nutr Exerc Metab. 2004;14(2):236-242
• Zhu JS, Halpern GM, Jones K. The scientific rediscovery of an ancient Chinese herbal medicine: Cordyceps sinensis Part I and Part II. J Altern Complement Med. 1998;4(3):289-303 and 4(4):429-457
• Song J, Wang Y, Teng M, et al. Cordyceps militaris fruit body extract ameliorates membranous glomerulonephritis by attenuating oxidative stress and renal inflammation. Food Chem Toxicol. 2015;76:76-83
• Tuli HS, Sandhu SS, Sharma AK. Pharmacological and therapeutic potential of Cordyceps with special reference to cordycepin. 3 Biotech. 2014;4(1):1-12
• Cunningham KG, Manson W, Spring FS, Hutchinson SA. Cordycepin, a metabolic product isolated from cultures of Cordyceps militaris (Linn.) Link. Nature. 1950;166(4231):949
• Paterson RRM. Cordyceps — a traditional Chinese medicine and another fungal therapeutic biofactory? Phytochemistry. 2008;69(7):1469-1495
• Das SK, Masuda M, Sakurai A, Sakakibara M. Medicinal uses of the mushroom Cordyceps militaris: current state and prospects. Fitoterapia. 2010;81(8):961-968
• Shashidhar MG, Giridhar P, Udaya Sankar K, Manohar B. Bioactive principles from Cordyceps sinensis: a review. J Funct Foods. 2013;5(3):1013-1030
• Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Vol 1. 2020 Edition
• Winkler D. Yartsa Gunbu (Cordyceps sinensis) and the fungal commodification of Tibet’s rural economy. Econ Bot. 2008;62(3):291-305
• Ng TB, Wang HX. Pharmacological actions of Cordyceps, a prized folk medicine. J Pharm Pharmacol. 2005;57(12):1509-1519

Connections

• Adaptogenic performance fungi/herbs: Compare with rhodiola (anti-fatigue, exercise performance via HPA axis modulation), eleuthero (adaptogenic endurance support), and astragalus (immune tonic and qi tonic in TCM). Cordyceps’ adenosine-analog mechanism is pharmacologically distinct from these adaptogens.
• Medicinal mushroom immunomodulators: Cordyceps beta-glucan immune activity parallels that of reishi (Ganoderma lucidum), turkey tail (Trametes versicolor), lion’s mane (Hericium erinaceus), and chaga (Inonotus obliquus). All share polysaccharide-driven innate immune activation, but cordyceps is unique in its concurrent adenosine-analog pharmacology.
• Species and sustainability: The ecological and economic dimensions of wild O. sinensis harvesting on the Tibetan Plateau represent one of the most significant conservation challenges in medicinal natural products. Cultivated C. militaris provides a sustainable, standardizable alternative with equivalent or superior cordycepin content.
• Form-dependent pharmacology: The distinction between C. militaris fruiting body (high cordycepin) and Cs-4 mycelium (clinical trial precedent, polysaccharide-focused) is critical for practitioners selecting products. This parallels the fruiting body vs. mycelium debate across medicinal mycology (e.g., lion’s mane hericenones vs. erinacines).
• Synergy potential: Traditional TCM formulas often combine cordyceps with astragalus (Huang Qi) for qi tonification and immune support. Modern integrative protocols may pair cordyceps with rhodiola for complementary anti-fatigue mechanisms (adenosine-analog + HPA axis modulation).